Pre-made Lirentelimab biosimilar ( Whole mAb, anti-SIGLEC8 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-315
Anti-SIGLEC8 therapeutic antibody (Pre-made Lirentelimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-SIGLEC8 therapeutic antibody (Pre-made Lirentelimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease|
|Conditions Discontinued||Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis|